HLA-A
HLA-A are a group of human leukocyte antigens (HLA) that are encoded by the HLA-A locus on human chromosome 6p. The HLA genes constitute a large subset of the Major histocompatibility complex (MHC) of humans. HLA-A is a component of certain MHC class I cell surface receptor isoforms that resides on the surface of all nucleated cells and platelets. The receptor is a heterodimer, and is composed of a heavy, alpha (α) chain and smaller beta (β) chain. The alpha chain is encoded by a variant HLA-A gene, and the beta chain (β2-microglobulin) is composed by the invariant Beta-2 microglobulin gene.
MHC Class I molecules are part of a process that presents polypeptides from host of foreign derivation to the immune system. Under normal conditions, if a peptide of foreign, pathogenic, source is detected, it alerts the immune system that the cell may be infected with a virus, and, thus, target the cell for destruction.
For humans, as in most mammalian populations, MHC Class I molecules are extremely variable in their primary structure, and HLA-A is ranked among the genes in humans with the fastest-evolving coding sequence. After typing millions of individuals, hundreds of variant alleles and isoforms have been identified.[1] This level of variation on MHC Class I is the primary cause of transplant rejection, as random transplantation between donor and host is unlikely to result in a matching of HLA-A, B or C antigens.
HLA-A gene
The HLA-A gene is part of the Human MHC complex on chromosome 6. The region is at the telomeric end of the HLA complex between the HLA-G and HLA-E genes. HLA-A gene encodes the larger, α-chain, constituent of HLA-A. Variation of HLA-A α-chain in certain ways is key to HLA function. This variation promotes diversity of class I recognition in the individual and also promotes genetic diversity in the population. This diversity allows more types of foreign, virus or cancer, antigens to be 'presented' on the cell surface, but also allows a subset of the population to survive if a new virus spreads rapidly through the population.
These changes are also key to inter-individual histocompatibility of organs and tissues. Difference in exposed structures of homologous proteins between individuals gives rise to antigen-antibody reactions when tissues are transplanted. This form of antigenicity gives rise to serotypes in tissue recipients. Refined serotypes are what scientists have used for grouping HLA.
There are many variant alleles of the gene. The HLA-A gene was discovered after a long process of determining MHC antigens. The original alleles discovered for MHC class I were not separated according to genes. The first 15 HL A1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 contained antigens from many HLA loci. HL A1, 2, 3, 9, 10, 11 were later found limited to a maximum of 2 in any given person. For example, a person could have A1, A2, A7, A8 but not A1, A2, A3, and A11 or A7, A8, A14, A15. Given the exclusion HLA-A alleles were sorted according A and B, creating HLA-A and HLA-B serotype groups, in late 1970s the first A and B isoforms were finally sequenced.[2][3]
Alleles
There are many alleles, so that classification by serotype simplifies categorization. For example HLA-A*0101, *0102, *0103, . . . *0130 are assigned to the serotype A1.[4] The A*01 prefix signifies that the gene products (expressed proteins) of the alleles are identified primarily by the A1 serotype or most similar to alleles recognized by the serotype. There is a useful logic in this classification: HLA alleles evolve by a process called 'gene conversion' in which a few (<50 nucleotides) are swapped between HLA haplotypes and often results in the change of 1 to 3 nucleotides on the converted chromosome. Infrequently, there are recombination events that cross-over a gene in the style of recombination we are familiar with in genetics. This can result in entirely new serotypes and alleles. Less frequently, single-nucleotide polymorphisms alter the gene (intro or exon) but can cause changes unseen at the protein level. These cryptic alleles are designated with further extension such as A*01010101 or A*01010102, but they are still A*0101 allele, also.
There are 673 gene alleles capable of producing 527 HLA-A isoforms and 46 nulls.[1]
Assignment of alleles
HLA alleles and specificity are assigned as a consequence of workshops and working groups. Some Allele groups have been updated with recent information from the IMGT/HLA Database [5] Explanation - within each allele group there are alleles that are recognized by the serological typing for that group (e.g., A24-serotype) some within the group may also recognize the broad antigen typing (A9, A10, A19, A28) or only the broad antigen typing, some by alternative serological within the group (e.g., A2403), and some by no serological method. Some groups are more closely related than other groups, which is often reflected in broad antigen reactivity.
Function
Natural function
MHC Class I molecules present smaller peptides, in general, 9 amino acids in length, but somewhat longer molecules are tolerated, to the immune system. Several target cells include CD8+ T-lymphocytes. In response to signaling, these lymphocytes result in programmed cell death (apoptosis). This mechanism is the result of responses to viral infection or intracellular microbial infections in which, as a means of preventing propagation, affected cells are killed and the antigens are presented to the immune system for Class II presentation and antibody development. Over a short period of time, antibodies that can neutralize the ability of viruses and invasive bacteria to invade cells develop.
Other activities
One major activity of HLA-A receptors resulted from the era of organ transplantation initiated after WWII. By the 1960s, it became evident that factors on the donated organs and tissues resulted in an inflammatory destruction of those transplants by the host. The MHC class I receptors were a primary target on donor tissues. As a consequence, donated organs must be matched with regard to HLA between donor and recipient.
In disease
HLA-A associated diseases
Associated disease |
Serotypes |
Ankylosing spondylitis |
A24 |
|
|
Diabetes, type-I[6] |
A1 |
A24 |
Hemochromatosis (lower CD8+ cells) |
A3 |
|
|
myasthenia gravis |
A3 |
A24 |
A30 |
Leukemia, T-cell, Adult |
A26 |
A68 |
|
Multiple sclerosis |
A3 |
|
|
Papilloma virus susept. |
A11 |
|
|
Spontaneous abortion |
A2 |
|
|
Associated Diseases
HLA often suffer a peculiar problem in genetics; many of the haplotypes associated with disease are very large, often millions of nucleotides. Therefore, associations with disease often mark a variable gene that is close to a susceptibility gene for a disease. Most of the susceptibility for inflammatory disease lies between HLA-B locus and HLA-DP locus, with a substantial fraction linked to DR-DQ haplotypes. There are a few diseases, however, that link to the region telomeric from HLA-B, which contains most of the Class I loci, HLA-F, HLA-G, and HLA-E, as well as other genes.
Diseases by Haplotype
A*02:Cw*16 : higher viral load in HIV[7]
A*23:B*14 : higher viral load in HIV[7]
A*23:Cw*07 : higher viral load in HIV[7]
A*30:Cw*03 : higher viral load in HIV[7]
Interactions
HLA-A has been shown to interact with CD8A,[8][9] Tapasin[10] and TAP1.[10]
References
- ^ a b "IMGT/HLA Database". http://www.ebi.ac.uk/imgt/hla/stats.html. Retrieved 2008-08-14. (update July 2008)
- ^ Trägårdh L, Rask L, Wiman K, Peterson PA (1979). "Primary structure of pooled, papain-solubilized HLA-A, -B, and -C antigens". Scand. J. Immunol. 10 (6): 597–600. doi:10.1111/j.1365-3083.1979.tb01395.x. PMID 542807.
- ^ Trowsdale J, Lee J, Kelly A, et al. (February 1984). "Isolation and sequencing of a cDNA clone for a human HLA-ABC antigen". Mol. Biol. Med. 2 (1): 53–61. PMID 6549041.
- ^ "Allele search IMGT/HLA Database". http://www.ebi.ac.uk/imgt/hla/allele.html. Retrieved 2008-08-14. Type "A*" to retrieve A alleles
- ^ Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Geraghty DE, Hansen JA, Hurley CK, Mach B, Mayr WR, Parham P, Petersdorf EW, Sasazuki T, Schreuder GM, Strominger JL, Svejgaard A, Terasaki PI, and Trowsdale J. (2005). "Nomenclature for factors of the HLA System, 2004". Tissue antigens 65 (4): 301–369. doi:10.1111/j.1399-0039.2005.00379.x. PMID 15787720.
- ^ Noble J, Valdes A, Bugawan T, Apple R, Thomson G, Erlich H (2002). "The HLA class I A locus affects susceptibility to type 1 diabetes". Hum Immunol 63 (8): 657–64. doi:10.1016/S0198-8859(02)00421-4. PMID 12121673.
- ^ a b c d Tang J, et al. (2002). "Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1". J. Virology 76 (16): 8276–84. doi:10.1128/JVI.76.16.8276-8284.2002. PMC 155130. PMID 12134033. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=155130.
- ^ Gao, G F; Tormo J, Gerth U C, Wyer J R, McMichael A J, Stuart D I, Bell J I, Jones E Y, Jakobsen B K (Jun. 1997). "Crystal structure of the complex between human CD8alpha(alpha) and HLA-A2". Nature (ENGLAND) 387 (6633): 630–4. doi:10.1038/42523. ISSN 0028-0836. PMID 9177355.
- ^ Gao, G F; Willcox B E, Wyer J R, Boulter J M, O'Callaghan C A, Maenaka K, Stuart D I, Jones E Y, Van Der Merwe P A, Bell J I, Jakobsen B K (May. 2000). "Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha". J. Biol. Chem. (UNITED STATES) 275 (20): 15232–8. doi:10.1074/jbc.275.20.15232. ISSN 0021-9258. PMID 10809759.
- ^ a b Paulsson, Kajsa M; Kleijmeer Monique J, Griffith Janice, Jevon Marc, Chen Shangwu, Anderson Per O, Sjogren Hans-Olov, Li Suling, Wang Ping (May. 2002). "Association of tapasin and COPI provides a mechanism for the retrograde transport of major histocompatibility complex (MHC) class I molecules from the Golgi complex to the endoplasmic reticulum". J. Biol. Chem. (United States) 277 (21): 18266–71. doi:10.1074/jbc.M201388200. ISSN 0021-9258. PMID 11884415.
External links
|
|
Major histocompatibility complex/
Human leukocyte antigen |
|
|
|
|
HLA-DM ( α, β) • HLA-DO ( α, β) • HLA-DP ( α1, β1) • HLA-DQ ( α1, α2, β1, β2, β3) • HLA-DR ( α, β1, β3, β4, β5)
Minor histocompatibility antigen
|
|
|
Other |
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|
PDB gallery
|
|
|
1akj: COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 AND THE T CELL CORECEPTOR CD8
|
|
1ao7: COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201
|
|
1b0g: CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A2.1)/BETA 2-MICROGLOBULIN/PEPTIDE P1049 COMPLEX
|
|
1b0r: CRYSTAL STRUCTURE OF HLA-A*0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP
|
|
1bd2: COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201
|
|
1duy: CRYSTAL STRUCTURE OF HLA-A*0201/OCTAMERIC TAX PEPTIDE COMPLEX
|
|
1duz: HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) IN COMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN
|
|
1eey: Crystal Structure Determination Of HLA A2 Complexed to Peptide GP2 with the substitution (I2L/V5L/L9V)
|
|
1eez: Crystal Structure Determination of HLA-A2.1 Complexed to GP2 Peptide Variant(I2L/V5L)
|
|
1hhg: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
|
|
1hhh: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
|
|
1hhi: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
|
|
1hhj: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
|
|
1hhk: THE ANTIGENIC IDENTITY OF PEPTIDE(SLASH)MHC COMPLEXES: A COMPARISON OF THE CONFORMATION OF FIVE PEPTIDES PRESENTED BY HLA-A2
|
|
1hsb: DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE
|
|
1i1f: CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
|
|
1i1y: CRYSTAL STRUCTURE OF HUMAN CLASS I MHC (HLA-A2.1) COMPLEXED WITH BETA 2-MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
|
|
1i4f: CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4-PEPTIDE COMPLEX
|
|
1i7r: CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1058
|
|
1i7t: CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-5V
|
|
1i7u: CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDE P1049-6V
|
|
1im3: Crystal Structure of the human cytomegalovirus protein US2 bound to the MHC class I molecule HLA-A2/tax
|
|
1jf1: Crystal structure of HLA-A2*0201 in complex with a decameric altered peptide ligand from the MART-1/Melan-A
|
|
1jht: Crystal structure of HLA-A2*0201 in complex with a nonameric altered peptide ligand (ALGIGILTV) from the MART-1/Melan-A.
|
|
1lp9: Xenoreactive complex AHIII 12.2 TCR bound to p1049/HLA-A2.1
|
|
1oga: A STRUCTURAL BASIS FOR IMMUNODOMINANT HUMAN T-CELL RECEPTOR RECOGNITION.
|
|
1p7q: Crystal Structure of HLA-A2 Bound to LIR-1, a Host and Viral MHC Receptor
|
|
1q94: Structures of HLA-A*1101 in complex with immunodominant nonamer and decamer HIV-1 epitopes clearly reveal the presence of a middle anchor residue
|
|
1qew: HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA-A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOMA-ASSOCIATED ANTIGEN 3 (RESIDUES 271-279)
|
|
1qr1: POOR BINDING OF A HER-2/NEU EPITOPE (GP2) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE
|
|
1qrn: CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A
|
|
1qse: STRUCTURE OF HUMAN A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R
|
|
1qsf: STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A
|
|
1qvo: STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANT NONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THE PRESENCE OF A MIDDLE ANCHOR RESIDUE
|
|
1s8d: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-3A
|
|
1s9w: Crystal Structure Analysis of NY-ESO-1 epitope, SLLMWITQC, in complex with HLA-A2
|
|
1s9x: Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQA, in complex with HLA-A2
|
|
1s9y: Crystal Structure Analysis of NY-ESO-1 epitope analogue, SLLMWITQS, in complex with HLA-A2
|
|
1t1w: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-3F6I8V
|
|
1t1x: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-4L
|
|
1t1y: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-5V
|
|
1t1z: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-6A
|
|
1t20: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9-6I
|
|
1t21: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9, monoclinic crystal
|
|
1t22: Structural basis for degenerate recognition of HIV peptide variants by cytotoxic lymphocyte, variant SL9, orthorhombic crystal
|
|
1tmc: THE THREE-DIMENSIONAL STRUCTURE OF A CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE MISSING THE ALPHA3 DOMAIN OF THE HEAVY CHAIN
|
|
1tvb: Crystal structure of Melanoma Antigen gp100(209-217) Bound to Human Class I MHC HLA-A2
|
|
1tvh: Crystal structure of Modified Melanoma Antigen gp100(209-T2M) Bound to Human Class I MHC HLA-A2
|
|
1w72: CRYSTAL STRUCTURE OF HLA-A1:MAGE-A1 IN COMPLEX WITH FAB-HYB3
|
|
1x7q: Crystal structure of HLA-A*1101 with sars nucleocapsid peptide
|
|
2av1: Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the E63Q and K66A mutations in the heavy chain.
|
|
2av7: Crystal structure of HTLV-1 TAX peptide Bound to Human Class I MHC HLA-A2 with the K66A mutation in the heavy chain.
|
|
2bck: Crystal Structure of HLA-A*2402 Complexed with a telomerase peptide
|
|
2bnq: STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
|
|
2bnr: STRUCTURAL AND KINETIC BASIS FOR HEIGHTENED IMMUNOGENICITY OF T CELL VACCINES
|
|
2c7u: CONFLICTING SELECTIVE FORCES AFFECT CD8 T-CELL RECEPTOR CONTACT SITES IN AN HLA-A2 IMMUNODOMINANT HIV EPITOPE.
|
|
2clr: THREE DIMENSIONAL STRUCTURE OF A PEPTIDE EXTENDING OUT ONE END OF A CLASS I MHC BINDING SITE
|
|
2f53: Directed Evolution of Human T-cell Receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without apparent cross-reactivity
|
|
2f54: Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity
|
|
2git: Human Class I MHC HLA-A2 in complex with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) peptide
|
|
2gj6: The complex between TCR A6 and human Class I MHC HLA-A2 with the modified HTLV-1 TAX (Y5K-4-[3-Indolyl]-butyric acid) peptide
|
|
2hla: SPECIFICITY POCKETS FOR THE SIDE CHAINS OF PEPTIDE ANTIGENS IN HLA-AW68
|
|
2hn7: HLA-A*1101 in complex with HBV peptide homologue
|
|
3hla: HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2.1
|
|
|
|